Skip to main content
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
DPV + LNG Vaginal Ring
Product Overview
Alternative Name:
Dapivirine (DPV) + levonorgestrel (LNG) vaginal ring
Development Status:
Active Development
Target:
Female
Mode:
Hormonal
Delivery Type:
Vaginal Ring
Duration Type:
Long-acting
Description:
A silicone intravaginal ring (IVR) that a woman inserts and leaves in place for 90 days. The ring releases a combination of dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), to prevent HIV and levonorgestrel, a synthetic progestin, to prevent unintended pregnancy.
Updated date:
May 30, 2018
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
dapivirine
,
levonorgestrel
Inactive material:
silicone
Potential Multi-Purpose Technology (MPT):
Yes
Duration:
90 days
Partner:
International Partnership for Microbicides
,
USAID
Status
Project Phase:
Early Development
Project Stage:
Pre-clinical
Status Details:
GMP manufacturing of Phase I supplies are ongoing. In collaboration with the NIH-funded Microbicide Trials Network (MTN), a U.S.-based Phase I trial is expected to begin in 2016.
Programmatic Considerations
Additional Information
Additional Information:
International Partnership for Microbicides website
Download Product Report
